9 known cases. View patent page →
Declaratory-judgment action listing the '219 patent among patents in the case, including 10,272,062; 10,736,866; 10,952,986; 7,851,506; and 8,731,963. Final disposition not confirmed.
Lead consolidated Hatch-Waxman action over Xyrem sodium oxybate. The ’506 patent was among the original patents-in-suit, along with the ’431, ’889, ’219, ’059, and the ’730 family. Resolved by settlement with no final judgment on the ’506 patent.
Related Jazz v. Roxane action listed for the ’506 patent family and consolidated into 2:10-cv-06108. Resolved as part of the Roxane settlement.
Lupin action consolidated into the Jazz v. Amneal consolidated litigation, 2:13-cv-00391.
D.N.J. docket listed on the Google Patents ’506 patent litigation record. Party identity and outcome were not confirmed in the narrative.
Antitrust/consumer class action alleging pay-for-delay. The complaint lists US 7,851,506 among the patents at issue; defendants include Roxane Laboratories, Inc.
Antitrust pay-for-delay action in S.D.N.Y. citing the ’506 patent and describing the Xyrem settlement-driven generic launch schedule.
2020 antitrust suit against Jazz listed among the cases citing the related Xyrem patent portfolio, including the ’506 patent.
Jazz Pharmaceuticals sued Ranbaxy Laboratories and Ranbaxy Inc. in a Hatch-Waxman ANDA patent infringement action over generic sodium oxybate referencing Xyrem. The complaint asserted multiple patents including U.S. Patent No. 8,461,203. The case was consolidated for all purposes into Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 13-391-ES-JAD, and administratively terminated.